115 related articles for article (PubMed ID: 37439391)
1. The relevance of ERG immunoexpression intensity for prostatic adenocarcinoma in radical prostatectomy of 635 samples.
Feitosa PMFA; Hirth CG; Silva-Fernandes IJL; Dornelas CA
APMIS; 2023 Sep; 131(9):465-471. PubMed ID: 37439391
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of Ets-related gene-transcriptional factor in adenocarcinoma prostate and its correlation with Gleason score.
Mannan R; Bhasin TS; Manjari M; Singh G; Bhatia PK; Sharma S
Indian J Pathol Microbiol; 2016; 59(4):489-495. PubMed ID: 27721279
[TBL] [Abstract][Full Text] [Related]
3. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.
Hoogland AM; Jenster G; van Weerden WM; Trapman J; van der Kwast T; Roobol MJ; Schröder FH; Wildhagen MF; van Leenders GJ
Mod Pathol; 2012 Mar; 25(3):471-9. PubMed ID: 22080055
[TBL] [Abstract][Full Text] [Related]
4. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y
Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318
[TBL] [Abstract][Full Text] [Related]
5. ERG expression is associated with increased risk of biochemical relapse following radical prostatectomy in early onset prostate cancer.
Huang KC; Dolph M; Donnelly B; Bismar TA
Clin Transl Oncol; 2014 Nov; 16(11):973-9. PubMed ID: 24796295
[TBL] [Abstract][Full Text] [Related]
6. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
[TBL] [Abstract][Full Text] [Related]
7. Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients.
Kimura T; Furusato B; Miki J; Yamamoto T; Hayashi N; Takahashi H; Kamata Y; van Leenders GJ; Visakorpi T; Egawa S
Pathol Int; 2012 Nov; 62(11):742-8. PubMed ID: 23121605
[TBL] [Abstract][Full Text] [Related]
8. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature.
Xu B; Chevarie-Davis M; Chevalier S; Scarlata E; Zeizafoun N; Dragomir A; Tanguay S; Kassouf W; Aprikian A; Brimo F
Hum Pathol; 2014 Mar; 45(3):488-97. PubMed ID: 24406017
[TBL] [Abstract][Full Text] [Related]
9. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Grupp K; Habermann M; Sirma H; Simon R; Steurer S; Hube-Magg C; Prien K; Burkhardt L; Jedrzejewska K; Salomon G; Heinzer H; Wilczak W; Kluth M; Izbicki JR; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Mod Pathol; 2014 Jan; 27(1):96-106. PubMed ID: 23887301
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality.
Spencer ES; Johnston RB; Gordon RR; Lucas JM; Ussakli CH; Hurtado-Coll A; Srivastava S; Nelson PS; Porter CR
Prostate; 2013 Jun; 73(9):905-12. PubMed ID: 23334893
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of the chromatin remodeler death-domain-associated protein in prostate cancer is an independent predictor of early prostate-specific antigen recurrence.
Tsourlakis MC; Schoop M; Plass C; Huland H; Graefen M; Steuber T; Schlomm T; Simon R; Sauter G; Sirma H; Minner S
Hum Pathol; 2013 Sep; 44(9):1789-96. PubMed ID: 23642739
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.
Brooks JD; Wei W; Hawley S; Auman H; Newcomb L; Boyer H; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; McKenney JK
PLoS One; 2015; 10(7):e0132343. PubMed ID: 26172920
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of ERG and PTEN protein expression in cribriform architecture prostate carcinomas.
Downes MR; Satturwar S; Trudel D; van der Kwast TH
Pathol Res Pract; 2017 Jan; 213(1):34-38. PubMed ID: 27913052
[TBL] [Abstract][Full Text] [Related]
14. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
[TBL] [Abstract][Full Text] [Related]
15. High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer.
Weidemann SA; Sauer C; Luebke AM; Möller-Koop C; Steurer S; Hube-Magg C; Büscheck F; Höflmayer D; Tsourlakis MC; Clauditz TS; Simon R; Sauter G; Göbel C; Lebok P; Dum D; Fraune C; Kind S; Minner S; Izbicki J; Schlomm T; Huland H; Heinzer H; Burandt E; Haese A; Graefen M; Heumann A
BMC Cancer; 2019 Oct; 19(1):944. PubMed ID: 31606028
[TBL] [Abstract][Full Text] [Related]
16. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
17. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
Grupp K; Höhne TS; Prien K; Hube-Magg C; Tsourlakis MC; Sirma H; Pham T; Heinzer H; Graefen M; Michl U; Simon R; Wilczak W; Izbicki J; Sauter G; Minner S; Schlomm T; Steurer S
Exp Mol Pathol; 2013 Oct; 95(2):227-34. PubMed ID: 23948277
[TBL] [Abstract][Full Text] [Related]
18. High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer.
Eichenauer T; Federlein F; Möller K; Chirico V; Kind S; Lennartz M; Lutz F; Hube-Magg C; Höflmayer D; Fisch M; Huland H; Heinzer H; Graefen M; Haese A; Schroeder C; Lebok P; Minner S; Simon R; Sauter G; Schlomm T; Wilczak W; Steurer S; Luebke AM
Pathology; 2020 Jun; 52(4):421-430. PubMed ID: 32317175
[TBL] [Abstract][Full Text] [Related]
19. ERG expression and prostatic adenocarcinoma.
Verdu M; Trias I; Roman R; Rodon N; Garcia-Pelaez B; Calvo M; Dominguez A; Banus JM; Puig X
Virchows Arch; 2013 Jun; 462(6):639-44. PubMed ID: 23703293
[TBL] [Abstract][Full Text] [Related]
20. ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma.
Morais CL; Guedes LB; Hicks J; Baras AS; De Marzo AM; Lotan TL
Hum Pathol; 2016 Sep; 55():117-25. PubMed ID: 27189342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
